Web Exclusives

PharmaTimes talks to David Logue, senior vice president of commercial strategy at Veeva

Jessica Foreman looks at arguments for and against private GP services

After the election, Brexit will finally become real. Pharma must be ready to engage or risks being left behind.

Merck’s Maria Rivas discusses findings from the Supporting Women With Cancer report, which reveals some of the challenges associated with screening for cancer in women, and what more could be done to support the earlier detection of cancer and improve chances of survival.

With pressure mounting on the health service, the need for greater operational efficiency is paramount and modern technologies promise a powerful solution

In a bid to find an answer to up-scaling production easily, manufacturers are turning to multi tip tooling, which is seeing a huge revival thanks to its ease and efficiency.

Vicki Osborne, principal research fellow at the Drug Safety Research Unit, considers the possibility of an opioid crisis in the UK.

Orlando Agrippa on how we can achieve better medicines optimisation and how this will reap rewards for everyone

Cooperation and collaboration between the NHS, government and industry will be key to turbocharging the discovery and delivery of a new wave of medical innovations for patients, says Haseeb Ahmad, managing director UK, Ireland and Nordics at Novartis Pharmaceuticals and Country President, Novartis UK.

How can the pharma industry best prepare for Brexit?

Harrison Gaiger, marketing manager of the Research Partnership, says working with patient advocacy groups is key to conducting effective rare disease research

Tips from Sam Rutley on how pharmaceutical suppliers can optimise their eCommerce offering

George MacGinnis, challenge director of healthy ageing at UKRI, says businesses need to wake up to the opportunities of our longer lives

Professor Mike Trenell says AI-powered mHealth interventions are allowing pharma and healthcare innovators to support vast numbers of people quickly and cost-efficiently, but we mustn’t lose sight of the patient’s needs in the race for new tech and services.

ISO IDMP has resumed central focus at EMA, so life sciences firms must step up their own activities if they are to achieve compliance in their marketing submissions by the expected deadline of 2021. AMPLEXOR’s Siniša Belina explores the best approach to maximising returns over the long term.